Effect of Imatinib on Suppression of Malaria Parasites in Patients With Uncomplicated Plasmodium Falciparum Malaria

HuLow15 enrolled

Overview

The purpose of this study is to determine the efficacy and safety of imatinib in combination with dihydroartemisinin plus piperaquine in the treatment uncomplicated P. falciparum malaria in adult male patients.

An exploratory study to examine the efficacy and safety of imatinib mesylate in combination with dihydroartemisinin plus piperaquine on suppression of parasitemia in patients with uncomplicated Plasmodium falciparum malaria. In vitro studies of P. falciparum parasitized erythrocytes demonstrate that inhibitors of the protein tyrosine kinase SYK prevent malaria parasite egress from infected red blood cells and thereby terminate the parasite's life cycle. Although no potent syk kinase inhibitors were approved for human use at the time of initiation of this study, a bcr-abl tyrosine kinase inhibitor (imatinib mesylate (Gleevec®)) that also exhibits off-target inhibition of syk tyrosine kinase, has been FDA-approved for treatment of a number of human malignancies including chronic myelogenous leukemia and GIST. Because imatinib can be taken daily for many years without significant toxicity, it can be used to obtain a preliminary indication of whether inhibition of erythrocyte syk kinase can suppress parasitemia in patients with P. falciparum malaria. In a phase 1 clinical trial on the same patient population, anti-malaria activity was observed with imatinib, with little or no accompanying toxicity. Because dihydroartemisinin plus piperaquine constitute the currently used standard-of-care therapy for malaria in Southeast Asia, the above trial will test the safety and efficacy of the combination of imatinib plus dihydroartemisinin and piperaquine in treatment of uncomplicated malaria. In this pilot study, the rate of decrease in peripheral blood parasitemia in 30 adult male patients with uncomplicated malaria will be compared to the same rate of decrease in parasitemia in 30 adult male patients treated solely with dihydroartemisinin plus piperaquine.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Plasmodium Falciparum Malaria

Interventions

Imatinib combination therapyDRUG

Imatinib plus dihydroartemisinin plus piperaquine

Dihydroartemisinin-piperaquineDRUG

Standard of care

Eligibility

Sex: ALLMin age: 18 YearsMax age: 50 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Gender: only adults are selected for the trial; note that female subjects cannot be women of child-bearing age. * Age: 18-50 years. * Target disease: Uncomplicated Plasmodium falciparum malaria Exclusion Criteria: * symptoms and signs of complicated malaria * including continuous high fever of over 390C, psychiatric disorders, confusion, other neurological symptoms, symptoms and signs of functional impairment of the organs such as lungs, kidneys or cardiovascular system; * symptoms and signs of liver damage or kidney damage * symptoms and signs of another complicating infection such as pneumonia, dengue fever, and other bacterial infection. * P. falciparum \> 25.000 / mm3 * WBC \<4000 and \>10.000 /mm3 * RBC \< 3.5x106/mm3 * Platelets \< 40.000 /mm3 * Hemoglobin \< 10 g/dL * ALT more than 200% of the upper limit (56 units/L) * AST more than 200% of the upper limit (40 units/L) * Blood creatine more than 75% of the upper limit (men: 1.2 mg/dL, women 1 mgdL) * Serum total protein \< 6 g/L * Glycemia \< 50 mg/dL\> 200 mg/dL * Standard urine test Serious alterations * Concomitant treatments Antimalarial Drugs Anticoagulant therapy

Locations (1)

A Tuc

Hương Hóa, Quang Tri, Vietnam

Outcomes

Primary Outcomes

Time to Parasite Clearance

Parasite clearance was determined by assessing the parasite count in blood, using thin film, thick film and qPCR analysis

Time frame: From baseline to the time point when the blood parasite count is zero (up to a maximum of 5 days)

28-day Cure Rate

28-day cure rate was defined as the percentage of participants with blood parasite count of zero after 28 days of treatment and no evidence of recurrent infection with the same parasite genotype after reduction of the asexual parasitemia. Follow up after treatment will only be performed in the case of complete clearance of parasites at D5 due to Imatinib treatment.

Time frame: Day 28

Secondary Outcomes

Frequency of adverse events

Adverse events (AEs) are defined as events possibly related to the study drug as judged by physician that occur within 1 week of beginning treatment with imatinib. 1. Incidence, severity, drug-relatedness, seriousness of adverse events 2. Laboratory values (biochemistry and haematology) 3. Vital signs

Time frame: Within 1 week of beginning treatment with imatinib

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.